Connect with us

Hi, what are you looking for?

Hard News Hard Hitting News Source Global Political News

Business News

Pfizer, US Ink $5.29B Deal For Possible COVID-19 Treatment

This image provided by Pfizer shows its COVID-19 pills. Drugmaker Pfizer said Tuesday, Nov. 16, 2021, it is submitting its experimental pill for U.S. authorization, setting the stage for a likely launch in coming weeks. (Pfizer via AP)

The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it.

Pfizer asked the Food and Drug Administration on Tuesday to authorize emergency use of the experimental pill, which has been shown to significantly cut the rate of hospitalizations and deaths among people with coronavirus infections.

The FDA is already reviewing a competing pill from Merck and will hold a public meeting on it later this month.

The price for Pfizer’s potential treatment amounts to about $529 per course. The U.S. has already agreed to pay roughly $700 per course of Merck’s drug for about 1.7 million treatments.

Pfizer said Thursday the price being paid by the U.S. government reflects the high number of treatment courses purchased through 2022.

The drugmaker said it also has started rolling submissions for approval in several other countries and there are advanced purchase agreements with other governments as well.

On Tuesday, Pfizer signed a deal a with U.N.-backed group to allow generic drugmakers to produce low-cost versions of the pill for certain countries. Merck has a similar deal for its pill, which was authorized in Britain earlier this month.

Pfizer reported earlier this month that its pill cut hospitalizations and deaths by 89% among high-risk adults who had early symptoms of COVID-19.

The company studied its pill in people who were unvaccinated and faced the worst risks from the virus due to age or health problems, such as obesity.

Pfizer wants the drug available for adults who have mild-to-moderate COVID-19 infections and are at risk of becoming seriously ill. That’s similar to how other drugs are currently used to treat the disease.

But all FDA-authorized COVID-19 treatments require an IV or injection given by a health professional at a hospital or clinic.

Pfizer has already booked more than $24 billion in global revenue so far this year from Comirnaty, its COVID-19 vaccine, which has quickly become the drugmaker’s top-selling product.

Shares of New York-based Pfizer Inc. edged up 25 cents to $51.12 in early trading.

Copyright 2021 Associated Press. All rights reserved.

Advertisement. Scroll to continue reading.

Source: https://apnews.com/article/coronavirus-pandemic-business-health-f8f3b777d1685610a9293d4feedc656f

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Business News

EUGENE, Ore. (AP) — Psilocybin tea, wind chimes and a tie-dye mattress await those coming to an office suite in Eugene to trip on...

Business News

WASHINGTON (AP) — President Joe Biden is trumpeting Medicare’s new powers to negotiate directly with drugmakers on the cost of prescription medications — but a poll shows that...

Business News

The U.S. government is taking aim at what has been an indomitable empire: Google’s ubiquitous search engine that has become the internet’s main gateway....

Accidents

LAHAINA, Hawaii (AP) — Ambulance and fire truck sirens wailed outside as Elsie Rosales stripped linens from king-sized mattresses at a beachfront resort in...

Copyright © 2023 Hard News Herd Hitting in Your Face News Source | World News | Breaking News | US News | Political News Website by Top Search SEO